Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1998-3-5
pubmed:abstractText
Serum levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinases-2 (TIMP-2) were evaluated as prognostic indicators of the recurrence of urothelial cancer. Sera were obtained from 127 healthy control subjects and 97 urothelial cancer patients who underwent complete resection and were measured for MMP-2 and TIMP-2 using a one-step enzyme immunoassay. The relationship between the serum MMP-2/TIMP-2 ratio and the recurrence of urothelial cancer was examined. The mean serum MMP-2/TIMP-2 ratio in the 31 advanced urothelial cancer patients with recurrence was significantly higher than that in the 22 patients without recurrence (P = 0.0029) and in the 44 superficial bladder cancer patients (P < 0.0001). The 1- and 3-year disease-free survival rates in the patients with high MMP-2/TIMP-2 ratios (50% and 12%) were significantly poorer than those of the patients with normal ratios (82% and 56%) (P = 0.0152). Univariate and multivariate analyses of recurrence demonstrated that the serum MMP-2/TIMP-2 ratio is a significant independent indicator of advanced urothelial cancer. Our results indicate that an imbalance between the serum levels of MMP-2 and TIMP-2 could be a new predictor of recurrence in advanced urothelial cancer patients.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-1645772, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-1655116, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-1694043, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-1699524, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-1703045, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-1732058, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-1997689, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-2009533, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-2156082, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-2793861, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-3416307, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-6243750, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-7693724, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-7857719, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-7923181, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-8062271, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-8062280, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-8077060, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-8149645, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-8158685, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-8221672, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-8287559, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-8344982, http://linkedlifedata.com/resource/pubmed/commentcorrection/9484825-8603416
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
77
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
650-5
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:9484825-Adult, pubmed-meshheading:9484825-Aged, pubmed-meshheading:9484825-Aged, 80 and over, pubmed-meshheading:9484825-Analysis of Variance, pubmed-meshheading:9484825-Disease-Free Survival, pubmed-meshheading:9484825-Female, pubmed-meshheading:9484825-Gelatinases, pubmed-meshheading:9484825-Humans, pubmed-meshheading:9484825-Male, pubmed-meshheading:9484825-Matrix Metalloproteinase 2, pubmed-meshheading:9484825-Metalloendopeptidases, pubmed-meshheading:9484825-Middle Aged, pubmed-meshheading:9484825-Neoplasm Recurrence, Local, pubmed-meshheading:9484825-Neoplasm Staging, pubmed-meshheading:9484825-Prognosis, pubmed-meshheading:9484825-Tissue Inhibitor of Metalloproteinase-2, pubmed-meshheading:9484825-Tumor Markers, Biological, pubmed-meshheading:9484825-Urinary Bladder Neoplasms
pubmed:year
1998
pubmed:articleTitle
Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer.
pubmed:affiliation
Department of Urology, Hyogo Medical Center for Adults, Akashi, Japan.
pubmed:publicationType
Journal Article